MHRA approves Mounjaro for diabetes and weight management
Betsy Goodfellow | January 26, 2024 | News story | Medical Communications | Diabetes, MHRA, Mounjaro, weight management
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that it has approved a four-dose version of the diabetes and weight management medicine Mounjara (tirzepatide) in the form of Mounjaro KwikPen.
The four-dose version is intended to cover a month’s treatment and is approved to treat adult patients with type 2 diabetes and for weight management in adults with a BMI of 30kg/m2 or more (obesity), or those with a BMI between 27-30kg/m2 (overweight) who have weight-related health problems including prediabetes, high blood pressure, high cholesterol or heart issues.
The drug is intended to be used in combination with a reduced calorie diet and increased physical activity.
Julian Beach MHRA interim executive director, Healthcare Quality and Access, commented: “The public health importance of safe and effective treatments to help manage diabetes and obesity, which can have a significant impact on people’s health, is clear. This approval enables access to the approved Mounjaro pen in a more convenient presentation of a month’s treatment, of one dose per week.”
Douglas Twenefour, head of care at Diabetes UK, added: “We hope the MHRA’s approval of this device will help people living with type 2 diabetes, who are eligible, to access this effective treatment. Supporting people with type 2 diabetes to lose weight and manage their blood sugar levels is key to reducing the risk of diabetes-related complications, and tirzepatide (Mounjaro) expands the range of treatment options available to help people achieve this.”
Betsy Goodfellow
Related Content
IMed Consultancy releases white paper on Digital Mental Health Technologies
IMed Consultancy, a consultancy and service provider for the medical and health technology sector, has …
Dual immunotherapy for bowel cancer now available under NHS
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in …
MHRA approve new treatment combo for transplant-ineligible multiple myeloma patients
The Medicine and Healthcare products Regulatory Agency (MHRA) has approved quadruplet therapy, SARCLISA (isatuximab) in …
